Targeting ATR/CHK1 pathway in acute myeloid leukemia to overcome chemoresistance

Laure David; Stéphane Manenti; Christian Récher; Jean-Sébastien Hoffmann; Christine Didier

doi:10.1080/23723556.2017.1289293

Targeting ATR/CHK1 pathway in acute myeloid leukemia to overcome chemoresistance

Mol Cell Oncol. 2017 Sep 18;4(5):e1289293. doi: 10.1080/23723556.2017.1289293. eCollection 2017.

Authors

Laure David^{1

2

3}, Stéphane Manenti^{1

2

3}, Christian Récher^{2

3

4}, Jean-Sébastien Hoffmann^{1

2

3}, Christine Didier^{1

2

3}

Affiliations

¹ Equipe Labellisée, La Ligue Contre Le Cancer, Toulouse, France.
² Laboratoire d'Excellence Toulouse Cancer Labex TOUCAN, Cancer Research Center of Toulouse, INSERM U1037, CNRS ERL5294, Toulouse, France.
³ Université Paul Sabatier, Toulouse, France.
⁴ Service d'hématologie, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France.

Abstract

Resistance of acute myeloid leukemia to current therapies leads to frequent relapses. Identification of molecular mechanisms involved in chemoresistance constitutes a key challenge to define new therapeutic concepts. Here, we show that the ATR/CHK1 pathway, essential in maintaining genomic stability, is involved in resistance and proliferation characteristics of leukemic cells.

Keywords: ATR and CHK1 kinases; Acute Myeloid Leukemia; Chemoresistance; DNA replicative stress.